GGrantIndex
← Leaderboards

Jeffrey N Weitzel

University Of Southern California

Google Scholar ↗PubMed ↗ORCID ↗
$10,932,306
Attributed
$13,122,013
Total exposure
21
Grants
16
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY2005–19
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19

Funding mix

By agency

NIH$13,122,013 · 21

By mechanism

R25$7,796,893 · 4
R01$1,704,138 · 1
M01$1,687,412 · 12
RC4$1,000,003 · 1
R21$678,567 · 1
R03$255,000 · 2

Top collaborators

Others in their field

Top investigators on “Cancer Risk”

Research focus

Cancer RiskClinical ResearchResourcesBaseCancer PreventionGeneticRisk AssessmentLearningCancer GeneticsDesignMalignant NeoplasmsEvaluationEducational WorkshopFundingParticipantResearch PersonnelUnited States National Institutes Of HealthInternetCommunitiesSkillsEducational CurriculumTrainingCompetenceGenetic Counseling

Grant awards (53)

Precision approaches to refining TP53-associated cancer risk$1,704,138
R01 · FY2019 · CA · contact PI
Cancer Genetics Professional Education in a Global Community of Practice$302,509
R25 · FY2019 · CA
Cancer Genetics Professional Education in a Global Community of Practice$280,269
R25 · FY2018 · CA
Cancer Genetics Professional Education in a Global Community of Practice$301,713
R25 · FY2017 · CA
Cancer Genetics Professional Education in a Global Community of Practice$289,041
R25 · FY2016 · CA
Cancer Genetics Professional Education in a Global Community of Practice$297,959
R25 · FY2015 · CA
Cancer Genetics Professional Education in a Global Community of Practice$312,541
R25 · FY2014 · CA
Cancer Genetics Professional Education in a Global Community of Practice$323,199
R25 · FY2013 · CA
Novel targeted therapies for BRCA-associated cancer$334,117
R21 · FY2011 · CA · contact PI
Clinical Cancer Genetics Community Network: A Sustainable Research Partnership$1,000,003
RC4 · FY2010 · CA · contact PI
Novel targeted therapies for BRCA-associated cancer$344,450
R21 · FY2010 · CA · contact PI
Cancer Genetics Career Development Program$220,638
R25 · FY2010 · CA · contact PI
CLINICAL TRIAL: HEREDITARY CANCER RISK FACTORS AND OUTCOME IN BREAST CANCER PATI$282,913
M01 · FY2009 · RR · contact PI
Cancer Genetics Career Development Program$220,445
R25 · FY2009 · CA · contact PI
Community Cancer Genetics and Research Training (Revision)$185,309
R25 · FY2009 · CA · contact PI
Community Cancer Genetics and Research Training (Revision)$92,268
R25 · FY2009 · CA · contact PI
Hereditary Breast Cancer and Novel Hispanic BRCA Mutations$83,000
R03 · FY2009 · CA · contact PI
CLINICAL TRIAL: BIOMARKERS, BREAST DENSITY, AND RISK REDUCTION PERSPECTIVES$8,115
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: MOLECULAR GENETIC STUDIES IN CANCER PATIENTS AND THEIR RELATIVES$275,196
M01 · FY2008 · RR · contact PI
Community Cancer Genetics and Research Training (Revision)$174,162
R25 · FY2008 · CA · contact PI
Cancer Genetics Career Development Program$85,677
R25 · FY2008 · CA · contact PI
CLINICAL TRIAL: BIOMARKERS, BREAST DENSITY, AND RISK REDUCTION PERSPECTIVES$52,878
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE II, OPEN-LABEL, NON-COMPARATIVE, INTERNATIONAL, MULTICEN$4,806
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: DESLORELIN, ESTRADIOL & TESTOSTERONE IN WOMEN AT HIGH RISK OF BR$2,417
M01 · FY2008 · RR · contact PI
Cancer Genetics Career Development Program$463,014
R25 · FY2007 · CA · contact PI
HEREDITARY CANCER RISK FACTORS AND OUTCOME IN BREAST CANCER PATIENTS ON HIGH$262,629
M01 · FY2007 · RR · contact PI
Community Cancer Genetics and Research Training (Revision)$169,014
R25 · FY2007 · CA · contact PI
BIOMARKERS, BREAST DENSITY, AND RISK REDUCTION PERSPECTIVES$22,291
M01 · FY2007 · RR · contact PI
Cancer Genetics Career Development Program$466,030
R25 · FY2006 · CA · contact PI
HEREDITARY CANCER RISK FACTORS AND OUTCOME IN BREAST CANCER PATIENTS ON HIGH$316,809
M01 · FY2006 · RR · contact PI
Community Cancer Genetics and Research Training (Revision)$190,124
R25 · FY2006 · CA · contact PI
BIOMARKERS, BREAST DENSITY, AND RISK REDUCTION PERSPECTIVES$25,041
M01 · FY2006 · RR · contact PI
CLINICAL CANCER GENETICS FELLOWSHIP PROGRAM$492,994
R25 · FY2005 · CA
HEREDITARY CANCER RISK FACTORS AND OUTCOME IN BREAST CANCER PATIENTS ON HIGH$230,504
M01 · FY2005 · RR
Clinical Cancer Genetics Education$217,120
R25 · FY2005 · CA
Community Cancer Genetics and Research Training (Revision)$207,102
R25 · FY2005 · CA
BIOMARKERS, BREAST DENSITY, AND RISK REDUCTION PERSPECTIVES$11,364
M01 · FY2005 · RR
DESLORELIN, ESTRADIOL &TESTOSTERONE IN WOMEN AT HIGH RISK OF BREAST CANCER$3,099
M01 · FY2005 · RR
CLINICAL CANCER GENETICS FELLOWSHIP PROGRAM$492,994
R25 · FY2004 · CA
Clinical Cancer Genetics Education$215,554
R25 · FY2004 · CA
Hereditary Cancer Risk Factor &Outcome in Breast Cancer$171,163
M01 · FY2004 · RR
Genetic Discrimination Knowledge in Primary Care$86,000
R03 · FY2004 · HG
Deslorelin, Estradiol &Testosterone in Women$18,187
M01 · FY2004 · RR
CLINICAL CANCER GENETICS FELLOWSHIP PROGRAM$492,994
R25 · FY2003 · CA
Clinical Cancer Genetics Education$214,464
R25 · FY2003 · CA
Genetic Discrimination Knowledge in Primary Care$86,000
R03 · FY2003 · HG
CLINICAL CANCER GENETICS FELLOWSHIP PROGRAM$492,994
R25 · FY2002 · CA
Clinical Cancer Genetics Education$200,935
R25 · FY2002 · CA
CLINICAL CANCER GENETICS FELLOWSHIP PROGRAM$395,830
R25 · FY2001 · CA
HEREDITARY CANCER RISK/OUTCOME IN BREAST CANCER PATIENTS$0
M01 · FY2000 · RR
DESLORELIN, ESTRADIOL, TESTOSTERONE: BREAST CANCER RISK$0
M01 · FY2000 · RR
DESLORELIN, ESTRADIOL, TESTOSTERONE: BREAST CANCER RISK$0
M01 · FY2000 · RR
HEREDITARY CANCER RISK/OUTCOME IN BREAST CANCER PATIENTS$0
M01 · FY2000 · RR